Clinical Trials Directory

Trials / Completed

CompletedNCT02973750

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

While significant progress has been made in the treatment and prognosis of ovarian cancer, this progress has mostly shown benefits for younger women. This study aims to understand two things: How body composition (the amount of muscle and water versus fat in in the body) affects the dose and side effects of chemotherapy; and the biological reason for the worse prognosis with aging. To get a good view of these effects, investigators are asking the help of both younger and older women for this project.

Conditions

Interventions

TypeNameDescription
PROCEDUREBaseline BiopsyBaseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
PROCEDURETissue CollectionTissue collection during debulking surgery.
PROCEDUREBlood DrawsBlood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.

Timeline

Start date
2016-10-20
Primary completion
2020-07-18
Completion
2020-07-18
First posted
2016-11-25
Last updated
2023-01-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02973750. Inclusion in this directory is not an endorsement.